University of Kentucky Markey Cancer Center researchers have discovered a promising new way to combat therapy-resistant ...

Bone metastases are at the center of advanced prostate cancer care, with over 90% of patients with metastatic prostate cancer expected to have bone involvement. 1 These metastatic ...

UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to ...

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic ...

Brain metastases from prostate cancer (PC) seem to be more ... Furthermore, docetaxel (the drug of choice for the first-line treatment of castration-resistant PC) cannot cross the blood–brain ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses ... 223), the bone resorption-targeting drug denosumab and an immunotherapy (sipuleucel ...

There are over 52,000 cases of prostate cancer each year ... is a programme to review and approve promising cancer drugs helping patients access treatments faster. It is coordinated by the US ...

Cancer is a leading cause of death worldwide but several ASX biotechs are focused on early detection and treatment to ...

The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer ...

ONTARIO—The Ontario government is connecting more people to care by being the first Canadian jurisdiction to publicly fund and administer PLUVICTO, a new treatment for advanced-stage prostate cancer, ...